Schedule 13D ownership disclosure
Boston Therapeutics, Inc.
Security class unavailable · CUSIP: 05351T100
Event date: 2020-05-01
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 8,800,000
- Percent of class
- 9.1000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001785982-20-000543
- Form type
- SC 13D
- Filer
- BIOXYTRAN, INC
- CIK
- CIK 1445815
- Filed
- Jun 15, 2020
- Reporting period
- May 01, 2020
- Description
- Schedule 13D beneficial ownership